OmniaBio in the News

Medipost, OmniaBio to enhance cooperation for CDMO business. The Korea Economic Daily, December 1, 2022.

 Avectas, CCRM and OmniaBio’s Collaboration to Accelerate the Manufacture of Edited iPSCs. Phacilitate website, November 30, 2022.

 Avectas, CCRM & OmniaBio Expand Their Collaboration to Accelerate the Manufacture of Edited iPSCs Using SOLUPORE Technology. Drug Development & Delivery, November 30, 2022.

Race is on to claim share of biomanufacturing market. Investment Monitor, November 23, 2022.

Resolution Therapeutics And CCRM Sign Collaboration Agreement To Develop And Scale Up Manufacturing For iPSC-Derived Macrophage Cell Therapies. Outsourced Pharma, November 7, 2022.

Government Engagement Bodes Well For [Canadian] Life Sciences. MarketScreener, October 26, 2022.

NGen appuie la fabrication commerciale de thérapies cellulaires et géniques au Canada. CScience, October 11, 2022.

Innovation and commercialization in Southern Ontario. Synapse Consortium Brochure, Page 20. October 6, 2022.

NGen invests $10.5 M in Canadian Gov’t Cell-, Gene-Therapy Project. DCAT Value Chain Insights, September 29, 2022.

The Short Report – September 28, 2022. Research Money, September 28, 2022.

OmniaBio brings biomanufacturing muscle to Ontario. BIOTECanada Insights, Fall 2022 issue.

NGen Invests $10.5M to Support Commercial Scale Manufacturing of Cell & Gene Therapies in Canada. Contract Pharma, September 22, 2022.

CHCH Evening News at 6: OmniaBio and NGen feature. CHCH-TV, September 20, 2022.

Meet Mitch: The CEO leading Canada’s largest CDMO dedicated to manufacturing for CGTs. Signals blog, September 15, 2022.

CBRE Helps Launch Game-Changing Biomanufacturing Facility For Hamilton. CBRE website, September 7, 2022.

OmniaBio shapes the future of regenerative medicine. Invest Ontario website, July 27, 2022.

Multiplex to deliver McMaster Innovation Park’s flagship OmniaBio B, Canada’s first gene therapy facility. Multiplex Global website, July 19, 2022.

OmniaBio shares expansion plans with Hamilton investment partners at Collision Conference (with video). Invest in Hamilton website, June 23, 2022.

A big investment in CCRM’s OmniaBio, feds seek to advance digital charter, forging a new oil sands alliance, launching a climate impact accelerator, and more. Research Money, June 22, 2022.

OmniaBio, Medipost Ink Acquisition and Investment Deal. Contract Pharma, June 7, 2022.

Canada aims to get a slice of the growing global market for cell and gene therapies. Toronto Star, May 18, 2022.

McMaster Innovation Park wants more residential dev. Real Estate News EXchange, May 16, 2022.

What’s A CDMO And Why Do Biotech Startups Need them? Let’s Ask Canada. Crunchbase News, May 5, 2022.

Healthcare Is a Cost. But It’s Also a Business Opportunity. Canadian Business, April 26, 2022.

Gene therapy manufacturing coming to McMaster Innovation Park. The Bay Observer, April 1, 2022.

Ontario antes up $580M for C&G therapy plant in Hamilton. Endpoints News, April 1, 2022.

Ontario invests $40 million to grow global life sciences sector at Hamilton’s McMaster Innovation Park. Toronto Star, April 1, 2022

Ontario invests in $580 million gene and cell therapy facility in Hamilton. CHCH-TV, March 31, 2022.

New gene- and cell-therapy manufacturing facility to launch in Hamilton with $580-million commitment. The Globe and Mail, March 31, 2022.

WATCH: Ontario economic development minister to make announcement in Hamilton at 1:30 p.m. CHCH-TV, March 31, 2022.

 

Contact us to learn more about how we can support your needs at cdmo@omniabio.com.